Please wait a minute...
Reviews in Cardiovascular Medicine  2021, Vol. 22 Issue (1): 247-256     DOI: 10.31083/j.rcm.2021.01.243
Original Research Previous articles |
The impact of COVID-19 on short-term prognosis of ST-segment elevation myocardial infarction patients receiving primary percutaneous coronary intervention in Wuhan China
Qing Lu1, †, Jiu-Long Wang2, †, Zhi-Nan Chen1, Wen-Bo Fu1, Hui-Jian Liu1, Shi-Fang Ding1, *()
1Department of Cardiology, General Hospital of Central Theater Command, Wuhan, 430070 Hubei, P. R. China
2The First School of Clinical Medicine, Southern Medical University, Guangzhou, 510515 Guangdong, P. R. China
Download:  PDF(1085KB)  ( 633 ) Full text   ( 29 )
Export:  BibTeX | EndNote (RIS)      
Abstract:
ST-segment elevation myocardial infarction (STEMI) is a common cardiovascular emergency for which timely reperfusion therapies are needed to minimize myocardial necrosis. The aim of this study was to investigate the impact of the COVID-19 pandemic and reorganization of chest pain centers (CPC) on the practice of primary percutaneous coronary intervention (PPCI) and prognosis of STEMI patients. This single-center retrospective survey included all patients with STEMI admitted to our CPC from January 22, 2020 to April 30, 2020 (during COVID-19 pandemic in Wuhan), compared with those admitted during the analogous period in 2019, in respect of important time points of PPCI and clinical outcomes of STEMI patients. In the present article, we observed a descending trend in STEMI hospitalization and a longer time from symptom onset to first medical contact during the COVID-19 pandemic as compared to the control period (4.35 h versus 2.58 h). With a median delay of 17 minutes in the door to balloon time (D2B), the proportion of in-hospital cardiogenic shock was significantly higher in the COVID-19 era group (47.6% versus 19.5%), and major adverse cardiac events (MACE) tend to increase in the 6-month follow-up period (14.3% versus 2.4%). Although the reorganization of CPC may prolong the D2B time, immediate revascularization of the infarct-related artery could be offered to most patients within 90 minutes upon arrival. PPCI remained the preferred treatment for patients with STEMI during COVID-19 pandemic in the context of timely implementation and appropriate protective measures.
Key words:  COVID-19      STEMI      PPCI      Chest pain center      Prognosis     
Submitted:  13 November 2020      Revised:  22 January 2021      Accepted:  24 January 2021      Published:  30 March 2021     
Fund: 
WJ2018H0068/Research Joint Project of Health and Family Planning Commission of Hubei Province
*Corresponding Author(s):  Shi-Fang Ding     E-mail:  shifangding116@163.com
About author:  These authors contributed equally.

Cite this article: 

Qing Lu, Jiu-Long Wang, Zhi-Nan Chen, Wen-Bo Fu, Hui-Jian Liu, Shi-Fang Ding. The impact of COVID-19 on short-term prognosis of ST-segment elevation myocardial infarction patients receiving primary percutaneous coronary intervention in Wuhan China. Reviews in Cardiovascular Medicine, 2021, 22(1): 247-256.

URL: 

https://rcm.imrpress.com/EN/10.31083/j.rcm.2021.01.243     OR     https://rcm.imrpress.com/EN/Y2021/V22/I1/247

[1] Peter A. McCullough, Raphael B. Stricker, Harvey A. Risch. Role of hydroxychloroquine in multidrug treatment of COVID-19[J]. Reviews in Cardiovascular Medicine, 2021, 22(3): 545-546.
[2] Matteo Beltrami, Simone Bartolini, Massimo Milli, Alberto Palazzuoli. The relevance of specific heart failure outpatient programs in the COVID era: an appropriate model for every disease[J]. Reviews in Cardiovascular Medicine, 2021, 22(3): 677-690.
[3] Sarah Fitzsimons, Robert N Doughty. Role of transthoracic echocardiogram in acute heart failure[J]. Reviews in Cardiovascular Medicine, 2021, 22(3): 741-754.
[4] Florina Caruntu, Diana Aurora Bordejevic, Mirela Cleopatra Tomescu, Ioana Mihaela Citu. Clinical characteristics and outcomes in acute myocardial infarction patients aged ≥65 years in Western Romania[J]. Reviews in Cardiovascular Medicine, 2021, 22(3): 911-918.
[5] Matthieu MILLION, Jean-Christophe LAGIER, Hervé TISSOT-DUPONT, Isabelle RAVAUX, Catherine DHIVER, Christelle TOMEI, Nadim CASSIR, Léa DELORME, Sébastien CORTAREDONA, Sophie AMRANE, Camille AUBRY, Karim BENDAMARDJI, Cyril BERENGER, Barbara DOUDIER, Sophie EDOUARD, Marie HOCQUART, Morgane MAILHE, Coralie PORCHETO, Piseth SENG, Catherine TRIQUET, Stéphanie GENTILE, Elisabeth JOUVE, Audrey GIRAUD-GATINEAU, Herve CHAUDET, Laurence CAMOIN-JAU, Philippe COLSON, Philippe GAUTRET, Pierre-Edouard FOURNIER, Baptiste MAILLE, Jean-Claude DEHARO, Paul HABERT, Jean-Yves GAUBERT, Alexis JACQUIER, Stéphane HONORE, Katell GUILLON-LORVELLEC, Yolande OBADIA, Philippe PAROLA, Philippe BROUQUI, Didier RAOULT. Early combination therapy with hydroxychloroquine and azithromycin reduces mortality in 10,429 COVID-19 outpatients[J]. Reviews in Cardiovascular Medicine, 2021, 22(3): 1063-1072.
[6] Lee Stoner, Mark Faghy, Ryan Conners. COVID-19 infection and cardiometabolic complications: short- and long-term treatment and management considerations[J]. Reviews in Cardiovascular Medicine, 2021, 22(2): 263-265.
[7] Edoardo Pancaldi, Greta Pascariello, Giuliana Cimino, Angelica Cersosimo, Ludovica Amore, Fabio Alghisi, Nicola Bernardi, Emiliano Calvi, Carlo Mario Lombardi, Enrico Vizzardi, Marco Metra. Thrombotic risk in patients with COVID-19[J]. Reviews in Cardiovascular Medicine, 2021, 22(2): 277-286.
[8] Ibrahim AlShahrani, Jagadish Hosmani, Vidya Gurram Shankar, Abdulaziz AlShahrani, Rafi Ahmad Togoo, Syed M Yassin, Shahrukh Khan, Shankargouda Patil. COVID-19 and cardiovascular system—a comprehensive review[J]. Reviews in Cardiovascular Medicine, 2021, 22(2): 343-351.
[9] Agata Bielecka-Dabrowa, Anna Cichocka-Radwan, Joanna Lewek, Filip Pawliczak, Marek Maciejewski, Maciej Banach. Cardiac manifestations of COVID-19[J]. Reviews in Cardiovascular Medicine, 2021, 22(2): 365-371.
[10] Paulino Alvarez, Alex Sianis, Jessica Brown, Abbas Ali, Alexandros Briasoulis. Chronic disease management in heart failure: focus on telemedicine and remote monitoring[J]. Reviews in Cardiovascular Medicine, 2021, 22(2): 403-413.
[11] Florina Căruntu, Diana Aurora Bordejevic, Bogdan Buz, Alexandru Gheorghiu, Mirela Cleopatra Tomescu. Independent predictors of in-hospital and 1-year mortality rates in octogenarians with acute myocardial infarction[J]. Reviews in Cardiovascular Medicine, 2021, 22(2): 489-497.
[12] Yu-Hao Zhao, Lei Zhao, Xin-Chun Yang, Pan Wang. Cardiovascular complications of SARS-CoV-2 infection (COVID-19): a systematic review and meta-analysis[J]. Reviews in Cardiovascular Medicine, 2021, 22(1): 159-165.
[13] Farah Yasmin, Syed Muhammad Shujauddin, Aisha Naeem, Adina Jabeen, Syed Muhammad Ismail Shah, Rohan Kumar Ochani, Osama Mohiuddin, Anosh Aslam Khan, Sumeen Jalees, Aminah Abdul Razzack, Shiza Salman, Shuja Abdul Karim Khan, Ahmad Mustafa, Hassan Mehmood Lak. Exploring the impact of the COVID-19 pandemic on provision of cardiology services: a scoping review[J]. Reviews in Cardiovascular Medicine, 2021, 22(1): 83-95.
[14] Andrew C. Berry, Russell S. Gonnering, Ivan Rodriguez, Qianying Zhang, Bruce B. Berry. Unfavorable hydroxychloroquine COVID-19 research associated with authors having a history of political party donations[J]. Reviews in Cardiovascular Medicine, 2021, 22(1): 191-198.
[15] Meor Azraai, Marcus McMahon, Ronald Dick. Case report of amiodarone-associated allergic pneumonitis amidst the COVID-19 pandemic[J]. Reviews in Cardiovascular Medicine, 2021, 22(1): 181-184.
No Suggested Reading articles found!